Breast Cancer Clinical Trials in New York, New York

96 studies are recruiting for breast cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 4

  1. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York, New York
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  2. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Weill Cornell Medicine, New York, New York
    Locations
    7 in total
    Run by
    Massachusetts General Hospital

    See if you can join NCT03990896 on ClinicalTrials.gov

  3. IMPACT Trial: Intervention to iMProve AdherenCe Equitably

    To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using…

    Stage
    Not phased
    Ages
    18 to 99
    Site
    Columbia University Medical Center, New York, New York
    Run by
    Columbia University

    See if you can join NCT05496829 on ClinicalTrials.gov

  4. Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

    This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Mount Sinai Beth Israel, New York, New York
    Locations
    3 in total
    Run by
    Icahn School of Medicine at Mount Sinai

    See if you can join NCT05095207 on ClinicalTrials.gov

  5. Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

    The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional pho…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The New York Proton Center, New York, New York
    Run by
    The New York Proton Center

    See if you can join NCT05313191 on ClinicalTrials.gov

  6. Breast Cancer Implementation Science Study With Educational Intervention

    A study uniquely focused on system-based practice change, measuring the impact of educational interventions on both patients and clinicians for the recognition and management of treatment-related adverse effects for HER2+/HER2 low breast cancer patients on or about to start on HER2 targeted antibod…

    Stage
    Not phased
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT06927895 on ClinicalTrials.gov

  7. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  8. Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

    The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT01788839 on ClinicalTrials.gov

  9. A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

    The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radi…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04683679 on ClinicalTrials.gov

  10. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  11. A Study of Revaree Plus in People With Breast Cancer

    The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07042581 on ClinicalTrials.gov

  12. Converting HR+ Breast Cancer Into an Individualized Vaccine

    Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms…

    Stage
    Phase 2
    Ages
    18 to 90
    Site
    New York Presbyterian Hospital - Queens, New York, New York
    Locations
    8 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT03804944 on ClinicalTrials.gov

  13. Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study

    The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed…

    Stage
    Not phased
    Ages
    19 to 90
    Site
    New York Presbyterian Hospital - Queens, New York, New York
    Locations
    3 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT04371913 on ClinicalTrials.gov

  14. Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol

    This study aims to assess whether gabapentin should be a standard component of peri-operative pain control in mastectomy patients at Memorial Sloan Kettering Cancer Center.

    Stage
    Phase 4
    Ages
    18 to 65
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07308717 on ClinicalTrials.gov

  15. De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You

    This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.

    Stage
    Not phased
    Ages
    18 to 90
    Site
    Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York
    Locations
    2 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05134779 on ClinicalTrials.gov

  16. Combined Immunotherapies in Metastatic ER+ Breast Cancer

    Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotacti…

    Stage
    Phase 2
    Ages
    18 to 90
    Site
    Weill Cornell Medicine, New York, New York
    Locations
    3 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT04563507 on ClinicalTrials.gov

  17. A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

    The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.

    Stage
    Phase 3
    Ages
    18 to 75
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06144164 on ClinicalTrials.gov

  18. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, New York, New York
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  19. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone, New York, New York
    Locations
    37 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

  20. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Kings County Hospital, New York, New York
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

  21. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.